Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly.

Next Previous
Trial Profile

Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Dexamethasone (Primary) ; Ofatumumab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 07 Dec 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
  • 15 Mar 2012 Actual initiation date changed from Apr 2010 to 2 Dec 2009 as reported by European Clinical Trials Database.
  • 10 Dec 2011 Interim results have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top